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The aim of the study was to analyze the antimicrobial susceptibility of Austrian clinical
Klebsiella sp. and Enterobacter sp. isolates linked to patient-related data over a time
period from 1998 to 2014. The main findings of this study were (i) a marked difference
of antibiotic susceptibility rates between different infection sites for both Klebsiella sp.
and Enterobacter sp., (ii) significantly greater percentages of resistant isolates among
both Klebsiella sp. and Enterobacter sp. in male patients compared to female patients
and (iii) significantly greater percentages of resistant isolates among both Klebsiella
sp. and Enterobacter sp. from hospital-derived samples compared to samples from
the community. In conclusion, our statistical data analysis clearly indicated a strong
association of patient-related data and Klebsiella sp. and Enterobacter sp. susceptibility
profiles.
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INTRODUCTION
Whereas the antibiotic resistance crisis in Gram-positive pathogens largely seems to be kept under
control, the emergence and dissemination of antibiotic resistance in Gram-negative pathogens risk
getting out of control (Arya et al., 2008; Slama, 2008; Bush et al., 2011; Livermore, 2012). To gain
useful information on overall trends in a speciﬁc region and alert for more eﬀective prevention and
control measures, surveillance studies based on large data sets are of particular importance in this
ﬁeld (World Health Organization [WHO], 2014). Multivariate statistical analysis further allows
studying possible relationships between antimicrobial resistance data and patient-related factors;
however, there are only a limited number of studies up to now on that issue mainly dealing with
Escherichia coli. The main ﬁndings of these studies are that susceptibilities to several antimicrobial
agents are strongly depending on infection site as well as patient location (hospital/community),
gender and age (Livermore et al., 2003; Miguel Sahuquillo-Arce et al., 2011; Badura et al., 2015).
Under the hypothesis that the same is true for Klebsiella sp. and Enterobacter sp., the aim of this
study is to analyze a large amount of antibiotic resistance data (almost 39.000 isolates) from our
geographical region according to patient-related factors. The application of multivariate statistical
analysis enables us to detect signiﬁcant associations between patient’s characteristics and the
percentages of resistant isolates what is of key importance to further identify possible risk factors
related to antibiotic-resistant Klebsiella and Enterobacter infections.
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TABLE 1 | Data basis for the statistical analysis.
Patient gender (%) Patient location (%) Number of isolates
Female Male Community Hospital
Klebsiella sp. 59.4 40.5 52.3 47.7 24024
Enterobacter sp. 52.8 47.1 44.0 56.0 14969
Total 38993
TABLE 2 | Overall resistance percentages of Klebsiella sp. and
Enterobacter sp.
Antibiotic Klebsiella sp. Enterobacter sp.
%R n/total %R n/total
AN 3.47 366/10550 0.96 78/8094
AMC 9.44 2264/23979
CAZ 7.19 1230/17102 20.55 2341/11389
CIP 6.43 1543/23995 5.2 778/14961
CTX 5.76 1370/23765 19.87 2943/14811
NF 24.43 2297/9404 30.71 1502/4891
GM 6.66 1458/21889 2.76 392/14216
IPM 0.89 60/6747 0.54 26/4839
MEC 3.73 120/3220
MEM 0.67 70/10511 0.28 22/7720
PT 6.98 1270/18186 20.17 2505/12418
SXT 10.82 2595/23990 6.22 930/14958
AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP,
ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM,
imipenem; MEC, mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT,
trimethoprim/sulfamethoxazole; %R, percentages of non-susceptible isolates.
MATERIALS AND METHODS
A total of 24.024 Klebsiella sp. and 14.969 Enterobacter sp.
isolates were included in the present analysis. The study design
of this retrospective observational study (data origin, laboratory
methods, and statistical analysis) is largely similar to our previous
report on E. coli (Badura et al., 2015). Data were retrieved from
the Laboratory of Medical Bacteriology and Mycology of the
Medical University of Graz, Austria from January 1998 to March
2014. In the event of multiple isolates from one person in a
year, only the ﬁrst one was considered. For each isolate, patient–
related data (age, gender), patient location (community/hospital)
and culture site were obtained. Culture sites were subdivided
into the following categories: urinary tract (UT), genital tract
(GT), wounds (WOU), respiratory tract (RES), and blood (BLO);
patient age was categorized as follows: <1, 1–9, 10–19, 20–29,
30–39, 40–49, 50–59, 60–69, 70–79,>= 80 years.
All isolates had been tested for antibiotic susceptibilities in the
routine microbiology laboratory in the same way as reported in
a previous study using the disk diﬀusion method or a VITEK
2 system (bioMérieux, Marcy lEtoile France) (Badura et al.,
2015). From January 1st, 1998 to May 31st, 2011 results were
interpreted using the criteria recommended by the Clinical
and Laboratory Standards Institute (CLSI), formerly known as
National Committee for Clinical Laboratory Standards (NCCLS)
(CLSI, 2012). From June 1st, 2011 results were interpreted
using the criteria recommended by the European Committee
on Antimicrobial Susceptibility Testing (EUCAST breakpoint
tables v1.2, 2011) in its respective current version. For this
study, resistance to the following 12 antibiotic agents was
analyzed: amikacin (AN), amoxicillin-clavulanic acid (AMC;
analyzed forKlebsiella sp. only), ceftazidime (CAZ), ciproﬂoxacin
(CIP), cefotaxime (CTX), nitrofurantoin (NF; analyzed for
urinary tract isolates only), gentamicin (GM), imipenem (IPM),
mecillinam (MEC; analyzed for Klebsiella sp. urinary tract
isolates only); meropenem (MEM), piperacillin/tazobactam
(PT), and trimethoprim/sulfamethoxazole (SXT). Resistant and
intermediate resistant isolates were combined.
Statistical Analysis
For each of the two microbes and for each antibiotic under
consideration, the absolute and relative frequencies of resistant
samples were determined in total, per culture site, patient
location, age group, gender and year of acquisition. In order
to assess the inﬂuence of the covariates on antibiotic resistance,
multivariable logistic regression analysis was performed. For
binary covariates, odds ratios and 95% conﬁdence intervals are
presented and are adjusted for year of acquisition, patient gender,
patient age, patient location and resistance phenotype; for culture
site a model containing the aforementioned covariates as well as
cultures site has been tested against a model without culture site
and p values from the respective Chi-square test are presented.
Statistical analysis was performed using the R package, version
3.1.1 and SPSS, version 21.0 (R Development Core Team, 2008;
IBM Corp, 2012).
Ethics Statement
The study was approved by the Ethics Committee of the Medical
University of Graz (26-502 ex 13/14); patient records were
anonymized prior to analysis.
RESULTS
The underlying data basis for the present analysis is shown
in Table 1. In total, 38.993 clinical isolates of Klebsiella
sp. and Enterobacter sp. were included in the statistical
analysis.
Species Distribution
Within the Klebsiella samples, K. pneumoniae (61%) and
K. oxytoca (27.1%) were the most frequently recovered species;
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FIGURE 1 | Annual antibiotic resistance percentages of Klebsiella sp. for selected antibiotics.
within the Enterobacter samples, E. cloacae complex (59.2%)
and E. aerogenes (15.4%) were the most frequently recovered
species.
Overall and Annual Resistance
Percentages
Table 2 shows the overall resistance percentages of all tested
isolates. For Klebsiella sp. isolates, NF (analyzed for UT isolates
only) and SXT showed the highest values, for Enterobacter sp.
the highest values were found for NF, CAZ, PT, and CTX.
For Klebsiella sp. isolates, most antibiotics (CAZ, CTX, NF,
CIP, SXT, IPM, and MEM) showed increasing percentages
of resistant isolates over time (Figure 1, Supplemental
Table S1). The percentages of resistant Enterobacter sp.
isolates did not change considerably over the investigational
period for the majority of antibiotic agents (Supplemental
Table S1).
Resistance Percentages According to
Patient-Related Data
Results of the multivariate analysis of the antibiotic resistance
patterns according to culture sites for both pathogens are
presented in Table 3. The ﬁndings reveal the lowest resistance
percentages from samples originating from the male or female
genital tract (GT). ForKlebsiella sp. isolates, the highest resistance
percentages for almost all antibiotics analyzed occurred in
blood infections. For Enterobacter, the highest resistance
percentages were found in isolates originating from blood (CAZ,
CTX, GM, PT, SXT), and urinary tract infections (AN, CIP)
(Table 3).
Antibiotic resistance patterns in relation to patient gender
are shown in Table 4. Resistance percentages for almost
all antibiotic agents analyzed are higher in male patients.
A signiﬁcant diﬀerence can be shown for all antibiotics except
for AN for Klebsiella sp. isolates and for AN, GM, IPM,
MEM, and PT for Enterobacter sp., respectively. Antibiotic
resistance patterns in relation to patient location are shown
in Table 5. Resistance percentages for almost all antibiotic
agents analyzed are signiﬁcantly higher in hospital treated
patients. This is true for both Klebsiella sp. and Enterobacter sp.
isolates.
Regarding the association between antibiotic resistance
percentages of Klebsiella sp. and Enterobacter sp. isolates
and patient age, the majority of antibiotics show a
balanced distribution except for CIP where a constant
increase with age can be shown for both pathogen groups
(Figure 2).
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DISCUSSION
We here report an observational study whose aim is to
analyze the susceptibility of Austrian clinical Klebsiella sp.
and Enterobacter sp. isolates linked to patient-related data.
The underlying database for this statistical analysis covers
the period from 1998 to 2014. A major limitation of the
present study is that it was not possible to link the data to
severity of disease and patient outcome as these data were
not available. Additionally, information about the patient’s
length of the hospital stay was not included in the analysis
which would have been useful for the classiﬁcation as
hospital or community acquired infections. In the present
work, infections were categorized depending on the patient’s
location at the moment the clinical sample was obtained.
The passage from CLSI to EUCAST guidelines in 2011
in Austria may further bias data comparability. Several
authors have reported an increase of antibiotic resistance
rates for certain Enterobacteriaceae species/drug combinations
following EUCAST breakpoints implementation (Hombach
et al., 2012; Wolfensberger et al., 2013). However, we did
not observe any artiﬁcial rise of antibiotic resistance at that
time indicating that the change of interpretation criteria
does not apparently impact the results of the large data set
analyzed.
In general, surveillance is a substantial basis in the combat
against antimicrobial resistance in both community and hospital
settings; a large number of resistance surveillance reports
thus exist about Klebsiella sp. and Enterobacter sp. isolates
from various parts of the world describing the current
resistance situation (Jones et al., 2004; Bedenic et al., 2010;
Gales et al., 2012; Badal et al., 2013; Kaye and Pogue,
2015). Furthermore, studies dealing with the association of
antimicrobial resistance data and speciﬁc factors depending on
the host are of major importance with regard to the identiﬁcation
of possible risk factors related to antibiotic-resistant infections.
Several studies aimed to ﬁnd various patient demographics
and clinical factors associated with the presence of antibiotic-
resistant Enterobacteriaceae isolates, however, most of them
involve particular infections, patient cohorts, anatomic sites or
speciﬁc resistance problems. These studies thus mostly cover a
small amount of isolates consequently limiting statistical data
processing (O’Fallon et al., 2010; Metan et al., 2013; Ivady
et al., 2015; Moini et al., 2015; Oliveira et al., 2015). Here
we present a comprehensive statistical analysis on associations
between patient-related data and the percentages of antibiotic
resistant Klebsiella sp. and Enterobacter sp. isolates referring
on a large database with almost 39.000 isolates from Austria.
The main ﬁndings of this study are (i) a marked diﬀerence of
antibiotic susceptibility rates between diﬀerent infection sites
for both Klebsiella sp. and Enterobacter sp., (ii) signiﬁcantly
greater percentages of resistant isolates among both Klebsiella
sp. and Enterobacter sp. in male patients compared to female
patients and (iii) signiﬁcantly greater percentages of resistant
isolates among both Klebsiella sp. and Enterobacter sp. isolates
from hospital-derived samples compared to samples from the
community.
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TABLE 4 | Antibiotic resistance percentages of Klebsiella sp. and Enterobacter sp. according to patient gender.
Klebsiella sp. %R (n/total) Enterobacter sp. %R (n/total)
Antibiotic Female Male OR Female Male OR
AN 3.2 (174/5396) 3.7 (192/5141) 1.16 [0.95, 1.44] 0.8 (28/3731) 1.1 (50/4355) 1.43 [0.89, 2.34]
AMC 7.4 (1053/14245) 12.5 (1210/9715) 1.78 [1.63, 1.94]
CAZ 5.9 (552/9398) 8.8 (677/7688) 1.55 [1.38, 1.74] 17.7 (990/5598) 23.3 (1350/5782) 1.13 [1.03, 1.25]
CIP 4.5 (647/14248) 9.2 (895/9728) 2.13 [1.92, 2.37] 3.3 (263/7899) 7.3 (515/7050) 2.2 [1.88, 2.57]
CTX 4.3 (611/14093) 7.9 (758/9653) 1.88 [1.68, 2.1] 17.4 (1361/7812) 22.6 (1580/6987) 1.1 [1.01, 1.2]
NF 22.4 (1392/6208) 28.3 (905/3196) 1.37 [1.24, 1.51] 28.2 (837/2972) 34.7 (665/1919) 1.23 [1.09, 1.4]
GM 4.8 (613/12791) 9.3 (844/9079) 2.04 [1.83, 2.27] 2.3 (170/7416) 3.3 (222/6788) 1.11 [0.9, 1.38]
IPM 0.5 (17/3464) 1.3 (43/3273) 2.7 [1.57, 4.87] 0.5 (12/2255) 0.5 (14/2578) 0.8 [0.37, 1.76]
MEC 3 (60/2012) 5 (60/1208) 1.62 [1.11, 2.36]
MEM 0.4 (19/5174) 1 (51/5326) 2.07 [1.24, 3.61] 0.3 (9/3509) 0.3 (13/4206) 1 [0.43, 2.43]
PT 5.3 (545/10257) 9.2 (724/7912) 1.35 [1.19, 1.52] 19.7 (1286/6523) 20.7 (1216/5887) 1.01 [0.93, 1.11]
SXT 9.3 (1321/14245) 13.1 (1273/9726) 1.3 [1.19, 1.43] 5.8 (457/7897) 6.7 (472/7049) 1.16 [1.01, 1.33]
AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEC,
mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole. OR, odd ratio
TABLE 5 | Antibiotic resistance percentages of Klebsiella sp. and Enterobacter sp. according to patient location.
Klebsiella sp. %R (n/total) Enterobacter sp. %R (n/total)
Antibiotic Outpatient Hospital OR Outpatient Hospital OR
AN 0.3 (10/2894) 4.6 (356/7656) 4.18 [2.24, 8.71] 0.6 (11/1782) 1.1 (67/6312) 1.39 [0.74, 2.83]
AMC 4.8 (602/12557) 14.6 (1662/11422) 2.43 [2.18, 2.71]
CAZ 4.5 (303/6703) 8.9 (927/10399) 1.32 [1.04, 1.69] 10.2 (369/3607) 25.3 (1972/7782) 2.97 [2.63, 3.37]
CIP 5.6 (700/12558) 7.4 (843/11437) 1.08 [0.96, 1.23] 4.5 (297/6587) 5.7 (481/8374) 1.22 [1.05, 1.43]
CTX 2.7 (335/12552) 9.2 (1035/11213) 2.39 [1.8, 3.18] 11.8 (775/6584) 26.4 (2168/8227) 2.67 [2.44, 2.93]
NF 21 (1376/6557) 32.3 (921/2847) 1.77 [1.59, 1.96] 26.1 (872/3339) 40.6 (630/1552) 1.82 [1.6, 2.07]
GM 2 (205/10465) 11 (1253/11424) 2.86 [2.4, 3.42] 0.7 (40/5847) 4.2 (352/8369) 4.48 [3.23, 6.39]
IPM 0.2 (4/1863) 1.1 (56/4884) 2.55 [1.01, 8.59] 0 (0/1032) 0.7 (26/3807) ∗
MEC 3.3 (78/2393) 5.1 (42/827) 1.3 [0.87, 1.93]
MEM 0.2 (4/2508) 0.8 (66/8003) 5.14 [2.09, 17.09] 0.1 (1/1534) 0.3 (21/6186) 5.79 [1.18, 104.62]
PT 3.4 (266/7892) 9.8 (1004/10294) 2.71 [2.34, 3.14] 18.3 (956/5219) 21.5 (1549/7199) 1.2 [1.09, 1.32]
SXT 9.5 (1190/12556) 12.3 (1405/11434) 0.95 [0.86, 1.05] 5.9 (387/6582) 6.5 (543/8376) 1.05 [0.91, 1.21]
AN, amikacin; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; CTX, cefotaxime; NF, nitrofurantoin; GM, gentamicin; IPM, imipenem; MEC,
mecillinam; MEM, meropenem; PT, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole. ∗Not estimable because of 0 resistant isolates in outpatient group.
OR, odd ratio
FIGURE 2 | Percentages of antibiotic resistance of Klebsiella sp. (A) and Enterobacter sp. (B) to CIP according to patient age.
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To our knowledge, this is the ﬁrst report to compare
percentages of antibiotic resistant Klebsiella sp. and Enterobacter
sp. isolates from diﬀerent infection sites within a speciﬁc
region. The highest resistance percentages for the majority of
antibiotics analyzed can be shown for both pathogen groups
originating from blood infections. This is in accordance with
previous statistical analyses on the association of the infection site
and Escherichia coli susceptibility proﬁles (Miguel Sahuquillo-
Arce et al., 2011; Badura et al., 2015). As reported for
Escherichia coli, Klebsiella sp. and Enterobacter sp. isolates
originating from the GT generally show the lowest resistance
percentages indicating that detection from this culture site often
represents the normal patient ﬂora. Interestingly, antibiotic-
resistant Klebsiella sp. and Enterobacter sp. infections within
our study collection derive mostly from men. The same
association between patient sex and antibiotic resistance was
previously shown for Escherichia coli, however, the underlying
cause remains as yet largely unclear (Livermore et al., 2003;
Miguel Sahuquillo-Arce et al., 2011; Badura et al., 2015).
Similar to the results from several other studies dealing
with antibiotic resistance percentages of Enterobacteriaceae
in community and hospital settings we found signiﬁcantly
greater resistance rates for both pathogen groups amongst
the hospital-derived isolates suggesting that the problem
of antibiotic resistance amongst Gram-negative pathogens
is still focused on hospital settings in our region (Boyd
et al., 2008; Ferjani et al., 2015; McKay and Bamford,
2015).
CONCLUSION
Our statistical data analysis clearly indicates a strong association
between patient characteristics (gender, localization, infection
site) and Klebsiella sp. and Enterobacter sp. susceptibility
proﬁles. To gain further insight in the correlation of bacterial
antibiotic resistance and its host, additional studies analyzing
large databases of microbiological information are of crucial
importance ultimately inﬂuencing local antimicrobial therapy
guidelines.
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